Wealth Effects LLC Has $2.93 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Wealth Effects LLC decreased its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 2.6% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 155,875 shares of the biotechnology company’s stock after selling 4,150 shares during the quarter. Arrowhead Pharmaceuticals accounts for approximately 1.0% of Wealth Effects LLC’s holdings, making the stock its 13th biggest holding. Wealth Effects LLC owned 0.13% of Arrowhead Pharmaceuticals worth $2,930,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. World Investment Advisors LLC grew its position in Arrowhead Pharmaceuticals by 3.8% in the third quarter. World Investment Advisors LLC now owns 19,132 shares of the biotechnology company’s stock valued at $371,000 after acquiring an additional 700 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 788 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Arrowhead Pharmaceuticals by 1.5% in the 3rd quarter. Wellington Management Group LLP now owns 61,904 shares of the biotechnology company’s stock worth $1,199,000 after purchasing an additional 886 shares during the last quarter. State of Alaska Department of Revenue increased its position in shares of Arrowhead Pharmaceuticals by 7.3% during the 3rd quarter. State of Alaska Department of Revenue now owns 14,417 shares of the biotechnology company’s stock worth $279,000 after purchasing an additional 980 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Arrowhead Pharmaceuticals by 5.3% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 30,262 shares of the biotechnology company’s stock valued at $586,000 after purchasing an additional 1,523 shares during the last quarter. 62.61% of the stock is owned by institutional investors.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ:ARWR opened at $20.25 on Tuesday. The company has a debt-to-equity ratio of 2.06, a current ratio of 6.74 and a quick ratio of 6.74. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $17.05 and a 1-year high of $36.72. The business has a 50-day moving average price of $20.76 and a two-hundred day moving average price of $21.92.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Piper Sandler decreased their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Sanford C. Bernstein cut their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. Chardan Capital restated a “buy” rating and set a $60.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, December 12th. Finally, StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research note on Friday, December 20th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals has an average rating of “Hold” and an average target price of $43.33.

Insider Transactions at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction dated Friday, December 27th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. Following the completion of the sale, the director now owns 36,740 shares in the company, valued at approximately $734,800. This represents a 7.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director William D. Waddill sold 3,748 shares of the firm’s stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $21.90, for a total value of $82,081.20. Following the transaction, the director now owns 44,125 shares in the company, valued at approximately $966,337.50. This trade represents a 7.83 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 147,432 shares of company stock worth $2,957,986 in the last quarter. 4.50% of the stock is owned by company insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.